Get the Stockscreener App
12.59
3.30%
-0.43
Pre-market:
12.80
0.21
+1.67%
Helus Pharma Inc stock is traded at $12.59, with a volume of 1.46M.
It is down -3.30% in the last 24 hours and down -3.30% over the past month.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
See More
Previous Close:
$13.02
Open:
$12.8
24h Volume:
1.46M
Relative Volume:
0.77
Market Cap:
$919.95M
Revenue:
-
Net Income/Loss:
$-148.00M
P/E Ratio:
-2.8421
EPS:
-4.4299
Net Cash Flow:
$-135.66M
1W Performance:
-10.20%
1M Performance:
-3.30%
6M Performance:
+179.16%
1Y Performance:
+0.00%
1-Day Range:
$12.28
$12.88
1-Week Range:
$12.10
$15.15
52-Week Range:
$3.76
$15.15
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
12.59 | 919.95M | 0 | -148.00M | -135.66M | -4.4299 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | TD Cowen | Buy |
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Stock (HELP) Latest News
Cybin (CYBN) Presented 12 Month HLP003 Efficacy Data At A Psychiatry Congress - simplywall.st
Cybin D/B/A Helus Pharma (HELP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention? - finance.yahoo.com
Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression - finance.yahoo.com
Cybin D/B/A Helus Pharma (HELP.NE) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cybin Inc. Common Stock (NASDAQ: HELP) Share Price, HELP Stock News, HELP Share Price & Updates - kalkine.ca
Helus Pharma at TD Cowen summit: late-stage psychedelic bet takes shape - Investing.com Canada
Cybin Inc. at TD Cowen Novel Mechanisms in Neuropsychiatry Conference (Virtual) Transcript - GuruFocus
Nearly 99% of Cybin (HELP) investors vote for a new name - Stock Titan
Cybin D/B/A Helus Pharma (HELP) stock price, news, quote and history - Yahoo Finance UK
HELP News Today | Why did Cybin stock go up today? $HELP - MarketBeat
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change - Investing News Network
Helus Pharma Shareholders Approve Name Change and Governance Resolutions - TipRanks
Helus Pharma shareholders approve name change from Cybin Inc. By Investing.com - Investing.com Nigeria
Helus Pharma shareholders approve name change from Cybin Inc. - Investing.com
Helus Pharma Announces Annual and Special Meeting Voting Results and Legal Name Change to Helus Pharma Inc. - quiverquant.com
Helus Pharma (HELP.NE) Shareholders Approve Legal Name Change from Cybin Inc., Directors Elected at Annual Meeting - kalkine.ca
Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board - MarketBeat
Cybin Inc. Annual Shareholders Meeting Transcript - GuruFocus
Phase 3 Depression Data Could Define The Case For Cybin Stock - simplywall.st
Phase 3 depression drug in focus as Cybin (HELP) CEO joins TD Cowen webcast - Stock Titan
Analysts Offer Insights on Healthcare Companies: Helus Pharma (HELP), Ultragenyx Pharmaceutical (RARE) and Novavax (NVAX) - The Globe and Mail
Helus Pharma (HELP.NE) CEO to Join TD Cowen Neuropsychiatry Summit Fireside Chat on September 23 - kalkine.ca
Cybin highlights Phase 3 psychedelic depression drug | HELP SEC FilingForm 6-K - Stock Titan
Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026 - Investing News Network
Helus Pharma presents data on depression drug candidate HLP003 By Investing.com - Investing.com Canada
Helus Pharma (HELP) Showcases Key HLP003 Data at Psych Congress 2026 Amid High Valuation Metrics - GuruFocus
A potential depression treatment has 12-month efficacy results. Helus Pharma is testing it in a late-stage study. - Stock Titan
Barclays Sees Buying Opportunity in Helus Pharma (HELP) Amid Sha - GuruFocus
Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003 - finance.yahoo.com
Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances - finance.yahoo.com
Helus Pharma Inc (HELP) Stock Price, Quote, News & History - benzinga.com
HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results - TradingView
HELP Initiates Coverage On by Barclays -- Rating Set to Overweig - GuruFocus
Helus Pharma at Morgan Stanley conference: a broader depression bet By Investing.com - Investing.com Nigeria
Helus Pharma at Morgan Stanley conference: a broader depression bet - Investing.com
Cybin Inc. at Morgan Stanley Global Healthcare Conference Transcript - GuruFocus
Cybin (CN:HELP) Falls 5.91% as Clinical-Stage Risk and Phase 3 Expectations Pressure Sentiment - kalkine.ca
Helus Pharma at Cantor conference: phase III readout in focus - Investing.com
Canaccord Genuity maintains Buy on Helus Pharma, cuts target to $42 - scanx.trade
Phase 3 depression drug in focus as Cybin's Helus Pharma (HELP) joins Morgan Stanley event - Stock Titan
Cybin (NASDAQ:HELP) Shares Down 5.5%Here's Why - MarketBeat
Helus Pharma to Participate at the Morgan Stanley 24th Annual Global Healthcare Conference in New YorkThu, 09/10/202607:30 - Helus Pharma
symbol__ Stock Quote Price and Forecast - CNN
Executive chair buys 95,000 Cybin (HELP) shares in latest stake filing - Stock Titan
Helus Pharma (Nasdaq: HELP) CEO joins NYC investor fireside chat on Sept. 14 - stocktitan.net
Cybin (HELP) growth chief buys 90,000 shares in $1.04M trade - Stock Titan
Helus Pharma to Participate at the H.C. Wainwright 28th Annual Global Investment Conference in New York - The Manila Times
Helus Pharma to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference - quiverquant.com
HELP Watch: What's Behind Cybin Inc.'s Latest Move - kalkine.ca
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
Helus Pharma Inc Stock (HELP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):